Stay updated on clinical development milestones and clinical trial approvals we are proud to help our sponsors achieve
OCT Clinical Trials, a leading CRO with operations in Eastern Europe, today announced that it has appointed Maxime Stevens as Chief Strategy and Development Officer. In her role, she is responsible for establishing business development vision, creating roadmaps for global expansion, driving operational excellence and leading short- and long-term global strategy growth operations for the entire company.
"It is both an honor and pleasure for me to be joining OCT Clinical Trials as their Chief Strategy and Development Officer," Stevens said. "The people are extremely skilled, experienced and passionate about not only our work, but also each other, our sponsors and our partners."
Maxime brings more than 25 years' experience in executive leadership, developing Global BD and Operations groups for both American and European companies, including United States Surgical Corporation, Cyberonics Inc., Pierrel Research International AG and Optimapharm. As CEO for Pierrel Research International AG, Maxime was instrumental in wholly restructuring a troubled global company with 28 offices, increasing investments, backlog and revenue pipelines by more than 200%, and securing SIX Swiss Exchange listing of the merged companies in 2014.
Maxime possesses a strong track record of driving long-term growth, operational excellence and expansion of new geographic and channel opportunities for prominent players in the industry. Her extensive international experience, most notably in MENA, Africa, Europe and the United States, is a valuable asset for OCT Clinical Trials as the company moves toward global expansion.
Maxime is also known for her seven-year period running operations for South Africa's branch of the World Health Organization (WHO). Maxime was recognized by WHO for Outstanding Contribution to Ethics in Business and Humanity, and was an Honored Member of International WHO's WHO of Professionals in both 2013 and 2014. She also sat for four years on the FDA advisory and ethical boards for Innovative Medical Device approvals.
"I look forward to supporting both strategic onward growth and success of the company, and inspiring our people to learn even more, and become even more. Our best work happens when we embrace making a difference — and then we achieve it," Maxime added.
Having already gained a sizable market share of trials in Eastern Europe and CIS region, OCT is now taking the significant step of expanding its presence into EMEA, Israel, South Africa, Europe and the United States. With this strategic reinforcement, they will continue to provide the tailor-made solutions they are already known for, now to a broader pool of pharma, biotech and medical device companies.
"We're a full-service CRO with over 300 projects in our portfolio, solid technological infrastructure and well-run processes with all the main sites within the Eastern European and CIS region," said Dmitry Sharov, OCT Group President. "We realize that our services and approach are in high demand, not only for sponsors within the region, but for companies worldwide. Maxime Stevens has the proven experience and expertise to strategically develop and drive our expertise into the global arena, and amplify the image of a CRO with an impeccable reputation."
September 23, 2019
* - Required fields